Macrogenics (MGNX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$175.1M

Revenue (quarter)

$32.8M

Revenue growth (year over year)

+377.97%

Gross profit (trailing twelve months)

$139.1M

Gross margin

79.44%

Net income (trailing twelve months)

−$14.6M

Net income (quarter)

$19.5M

Net income growth (year over year)

+153.83%

Net margin

−8.33%

Return on equity

−32.61%

EPS (trailing twelve months)

−$0.22

Book value per share

$0.67

P/E (trailing twelve months)

—

Price to book

5.08

Debt to assets

87.59%

Payout ratio

—

Dividend yield

—

Company profile

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

• Is Macrogenics (MGNX) profitable?

  No. Macrogenics reported a net loss of $14.6M over the trailing twelve months.

• How much revenue does Macrogenics (MGNX) make?

  Macrogenics generated $175.1M in revenue over the trailing twelve months, up 377.97% year over year.

• How do I buy stock in Macrogenics (MGNX)?

  MGNX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.